目的 探讨雷贝拉唑钠肠溶片和枸橼酸莫沙必利片治疗及维持治疗糜烂性食管炎的疗效.方法 将134例经临床确诊为糜烂性食管炎的患者随机分为A、B、C三组.A组予雷贝拉唑10mg,每天2次,莫沙必利5mg,每天3次,治疗8周;8周后,予雷贝拉唑10mg,每天1次,莫沙必利5mg,每天3次,维持24周.B组予雷贝拉唑10mg,每天2次,莫沙必利5mg,每天3次,治疗8周;8周后,予雷贝拉唑10mg,每天1次,维持24周.C组:予法莫替丁20mg,每天2次,莫沙必利5mg,每天3次,治疗8周;8周后,予法莫替丁20mg,每天1次,维持24周.比较3组疗效和复发率.结果 雷贝拉唑联合莫沙必利能有效缓解反流症状(P＜0.05),降低食管炎症分级(P＜0.01),效果优于法莫替丁(P＜0.05).雷贝拉唑联合莫沙必利组的总有效率和复发率分别为100％和6.7％,与单用雷贝拉唑组(97.8％,17.8％)和单用法莫替丁组(86.3％,34.1％)相比差异有显著性(P＜0.05).结论 雷贝拉唑钠肠溶片联合枸橼酸莫沙必利片治疗和维持治疗糜烂性食管炎效果显著,复发率低.%Objective To investigate the effect of sodium rabeprazole enteric — coated tablets combined with mosapride citrate tablets in treating erosive esophagitis. Methods A hundred and thirty - four patients with erosive esophagitis were randomly divided into group A,B and C. Patients in group A were given rabeprazole 10 mg bid and mosapride 5 mg tid for 8 weeksjthen rabeprazole 10 mg qd and mosapride 5 mg tid for 24 weeks. Patients in group B were received rabeprazole 10 mg bid and mosapride 5 mg tid for 8 weeks; then rabeprazole 10 mg qd for 24 weeks. Patients in group C were treated with famotidine 20 mg bid and mosapride 5 mg tid for 8 weeks; then famolidine 20 mg qd for 24 weeks. The effect and relapse rate of the different treatment were compared. Results Better than famotidine( P < 0. 05) , the symptom of refluxing( P < 0. 05) and esophagitis( P < 0. 01) were remarkably released by treating with rabeprazole combined mosapride. The efficiency and relapse rate were 100% and 6.7% in group A, better than group B(97. 8% , 17. 8% )and group C(86. 3% ,34. 1% ), P < 0. 05. Conclusion Treating with sodium rabeprazole enteric - coated tablets combined with mosapride citrate tablets can get better efficiency and lower relapse rate.
展开▼
